Heterogeneity of KRAS Mutation Status in Rectal Cancer.

Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Peter Jo, Alexander König, Markus Schirmer, Julia Kitz, Lena-Christin Conradi, Azadeh Azizian, Markus Bernhardt, Hendrik A Wolff, Marian Grade, Michael Ghadimi, Philipp Ströbel, Hans-Ulrich Schildhaus, Jochen Gaedcke
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Online Access:	http://europepmc.org/articles/PMC4827807?pdf=render

Similar Items

Impact of Portal Vein Resection (PVR) in Patients Who Underwent Curative Intended Pancreatic Head Resection
by: Markus Bernhardt, et al.
Published: (2023-11-01)

Perioperative LiMAx Test Analysis: Impact of Portal Vein Embolisation, Chemotherapy and Major Liver Resection
by: Felix Rühlmann, et al.
Published: (2024-01-01)

Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial
by: Jochen Gaedcke, et al.
Published: (2025-02-01)

Short- and Long-Term Outcomes of Patients with Postoperative Arrhythmia after Liver Surgery
by: Felix Rühlmann, et al.
Published: (2024-01-01)

Distinct Chromosomal Profiles in Metastasizing and Non-Metastasizing Colorectal Carcinomas
by: B. Michael Ghadimi, et al.
Published: (2006-01-01)

Characterizing MRI features of rectal cancers with different KRAS status
by: Yanyan Xu, et al.
Published: (2019-11-01)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
by: Marie-Laure Amram, et al.
Published: (2017-11-01)

The Impact of Molecular Pathology in Oncology: The Clinician’s Perspective
by: Marian Grade, et al.
Published: (2004-01-01)

Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
by: Becker Heinz, et al.
Published: (2010-04-01)

Genome analysis of Cephalotrichum gorgonifer and identification of the biosynthetic pathway for rasfonin, an inhibitor of KRAS dependent cancer
by: Andreas Schüller, et al.
Published: (2023-06-01)

Effect of KRAS mutation status on clinicopathological characteristics and overall survival in patients with rectal cancer
by: Shengbin Zheng, et al.
Published: (2025-01-01)

Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
by: Sara Cherri, et al.
Published: (2023-01-01)

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
by: Sebastian Schade, et al.
Published: (2022-02-01)

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
by: Constanza Tapia Contreras, et al.
Published: (2025-02-01)

Integrated real-time imaging of executioner caspase dynamics, apoptosis-induced proliferation, and immunogenic cell death using a stable fluorescent reporter platform
by: Selen Selcen, et al.
Published: (2025-08-01)

KRAS status predicted by pretreatment MRI radiomics was associated with lung metastasis in locally advanced rectal cancer patients
by: Yirong Xiang, et al.
Published: (2023-12-01)

SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer
by: Yuuki Ohara, et al.
Published: (2023-12-01)

Rectal Cancer Presenting with Absceding Infection Due to <i>Fusobacterium nucleatum</i>
by: Sebastian Zundler, et al.
Published: (2022-09-01)

Molecular Cytogenetics: Genomic Imbalances in Colorectal Cancer and their Clinical Impact
by: Marian Grade, et al.
Published: (2006-01-01)

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
by: Yuchan Li, et al.
Published: (2022-07-01)

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review
by: Michal Eid, et al.
Published: (2022-12-01)

MRI T2WI-based radiomics combined with KRAS gene mutation constructed models for predicting liver metastasis in rectal cancer
by: Jiaqi Ma, et al.
Published: (2024-10-01)

Marijan Kraš
by: Andrea Toljan, et al.
Published: (2023-11-01)

A pan-KRAS degrader for the treatment of KRAS-mutant cancers
by: Jie Yang, et al.
Published: (2024-06-01)

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group
by: Maximilian Fleischmann, et al.
Published: (2022-05-01)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
by: Kohei Maruyama, et al.
Published: (2025-01-01)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
by: Kristina A. M. Arendt, et al.
Published: (2022-03-01)

Multimodal treatment according to the NPC‐GPOH trials in adult patients with nasopharyngeal cancer—Analysis based on a single‐center experience
by: Martin Leu, et al.
Published: (2024-08-01)

Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome
by: Sebastian Winkler, et al.
Published: (2016-01-01)

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
by: Kushtrim Kryeziu, et al.
Published: (2021-09-01)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
by: Xi Zhong, et al.
Published: (2020-05-01)

Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks
by: Lukas Perkhofer, et al.
Published: (2019-01-01)

The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer
by: Yebohao Zhou, et al.
Published: (2024-05-01)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
by: Alice Indini, et al.
Published: (2021-05-01)

Influence of mental effort on sound evaluations in virtual and real experimental environments
by: Hendrik Himmelein, et al.
Published: (2025-10-01)

Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
by: Shilpa Patil, et al.
Published: (2021-12-01)

A short history of »Kras«
by: Andrej Kranjc
Published: (2018-12-01)

Kras in metastatic colorectal cancer
by: A Wicki, et al.
Published: (2010-11-01)

Clinical Significance of the KRAS Mutation
by: Sead Beganovic
Published: (2010-10-01)

KRAS inhibitors: going noncovalent
by: Matthias Drosten, et al.
Published: (2022-12-01)